GERN Geron Corp

Item 2.02 Results of Operations and Financial Condition.

Geron Corporation (the “Company” or “Geron”) will participate in various virtual meetings with securities analysts and investors during the J.P. Morgan 40th Annual Healthcare Conference from January 10, 2022 through January 14, 2022 and will utilize a presentation handout during those meetings. Such presentation handout discloses that Geron expects to report that, as of December 31, 2021, it had cash, cash equivalents, restricted cash and marketable securities of approximately $210.0 million and a principal outstanding balance of $50.0 million in long-term debt. The aforementioned financial information is included on slide #24 of the presentation handout, as furnished in Exhibit 99.1 to this Current Report. Geron’s expectation is a forward-looking statement and Geron’s actual results for the year ended December 31, 2021 could differ, perhaps materially, from its current expectation as a result of certain factors, including, without limitation, risks related to changes in estimated cash position based on the completion of financial closing procedures, final audit adjustments and the audit of Geron’s financial statements.

The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 to this Current Report shall be deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing made by the Company with the U.S. Securities and Exchange Commission under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.